Application of lactobacillus paragrangii and metagen of lactobacillus paragrangii

Abstract

The invention relates to the field of microorganisms, and discloses application of lactobacillus paragasseri and a metagen of the lactobacillus paragasseri. The Lactobacillus paragrangii with the preservation number of CGMCC No.36335 provided by the invention can scavenge free radicals, has broad-spectrum bacteriostasis, has SOD (superoxide dismutase) enzyme activity, reduces the content of malonaldehyde, realizes high yield of tea polyphenols and flavones, has antioxidant and anti-aging capabilities, and can be used for preparing non-medical cosmetics.

Description

Technical Field

[0001] This invention relates to the field of microbiology, specifically to the application of Lactobacillus paragernii and its postbiotics. Background Technology

[0002] With increasing awareness of healthy skincare, natural, safe, and effective cosmetic ingredients have become a hot topic in industry research and development. Excessive accumulation of free radicals, imbalance of skin microecology, and aggravated oxidative stress are the core causes of skin aging and deterioration. However, traditional cosmetic ingredients mostly rely on chemically synthesized components, which are difficult to meet consumers' needs for gentle and effective skincare.

[0003] Microorganisms, due to their naturalness, biocompatibility, and diverse functions, are gradually becoming a new type of high-quality raw material in the cosmetics industry. Lactobacillus paragernii, as an important category of probiotics, can improve skin condition through mechanisms such as regulating the skin's microecology, inhibiting the growth of harmful bacteria, and scavenging free radicals. However, current research on the application of Lactobacillus paragernii in the cosmetics field is limited, lacking specific strains and related postbiotic products with clearly defined combined effects such as antioxidant, anti-aging, and broad-spectrum antibacterial properties.

[0004] Therefore, there is an urgent need to provide Lactobacillus paragerens with free radical scavenging, broad-spectrum antibacterial, and antioxidant capabilities and to apply it to the preparation of non-medical cosmetics. Summary of the Invention

[0005] The purpose of this invention is to overcome the above-mentioned problems existing in the prior art and to provide the application of Lactobacillus paragernii and its postbiotic.

[0006] To achieve the above objectives, the first aspect of the present invention provides *Lactobacillus paragelii* (… Lactobacillus paragassers The Lactobacillus paragelii is used in the preparation of anti-aging formulations, with the preservation number of the Lactobacillus paragelii being CGMCC No. 36335.

[0007] A second aspect of the present invention provides the use of *Lactobacillus paragrigius* in the preparation of an antioxidant formulation, wherein the *Lactobacillus paragrigius* has the accession number CGMCC No. 36335.

[0008] The third aspect of this invention provides the application of *Lactobacillus paragelius* in in vitro free radical scavenging, wherein the preservation number of *Lactobacillus paragelius* is CGMCC No. 36335.

[0009] The fourth aspect of this invention provides the application of *Lactobacillus paragrigius* in the preparation of cosmetics, wherein the preservation number of *Lactobacillus paragrigius* is CGMCC No. 36335.

[0010] The fifth aspect of this invention provides the application of *Lactobacillus paragelius* in inhibiting the proliferation of pathogenic bacteria in vitro, wherein the preservation number of *Lactobacillus paragelius* is CGMCC No. 36335.

[0011] The sixth aspect of the present invention provides a heat-inactivated postbiotic, which is prepared from Lactobacillus parageri with accession number CGMCC No. 36335.

[0012] The seventh aspect of the present invention provides a post-lysis biotic, which is prepared from Lactobacillus parageri with accession number CGMCC No. 36335.

[0013] Through the above technical solution, the beneficial effects obtained by the present invention include at least the following: the *Lactobacillus paragernis* CCNH500 provided by the present invention can produce high levels of lipoteichoic acid, and has the prospect of industrial production of lipoteichoic acid; moreover, the *Lactobacillus paragernis* CCNH500 provided by the present invention can scavenge free radicals, has SOD enzyme activity, reduces MDA content, produces high levels of tea polyphenols and flavonoids, and has antioxidant and anti-aging capabilities.

[0014] Biological Preservation The strain provided by this invention is classified as *Lactobacillus parageri*. Lactobacillus paragasseri It was deposited on October 24, 2025, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 36335, located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing. Detailed Implementation

[0015] The endpoints and any values ​​of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of the various ranges, the endpoint values ​​of the various ranges and individual point values, and individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.

[0016] The inventors of this invention accidentally obtained a strain of *Lactobacillus paragernis* that has a laxative effect and produces a high amount of lipoteichoic acid during their research. Lactobacillus paragasseri The bacteria, named CCNH500, were further studied and found that the bacteria and their metabolites can also scavenge free radicals and inhibit pathogenic bacteria, showing promise for the preparation of non-medical cosmetics.

[0017] Based on the above findings, the first aspect of the present invention provides *Lactobacillus paragrigii* (… Lactobacillus paragassersThe Lactobacillus paragelii is used in the preparation of anti-aging formulations, with the preservation number of the Lactobacillus paragelii being CGMCC No. 36335.

[0018] A second aspect of the present invention provides the use of *Lactobacillus paragrigius* in the preparation of an antioxidant formulation, wherein the *Lactobacillus paragrigius* has the accession number CGMCC No. 36335.

[0019] Preferably, the substance having the anti-aging and / or antioxidant properties includes at least one of superoxide dismutase, tea polyphenols, and flavonoids.

[0020] Preferably, the anti-aging and / or anti-oxidation further includes reducing the content of oxidizing substances; more preferably, the oxidizing substances include malondialdehyde.

[0021] The third aspect of this invention provides the application of *Lactobacillus paragelius* in in vitro free radical scavenging, wherein the preservation number of *Lactobacillus paragelius* is CGMCC No. 36335.

[0022] Preferably, the free radicals include DPPH free radicals, hydroxyl free radicals, and ABTS free radicals. + At least one of the free radicals.

[0023] The fourth aspect of this invention provides the application of *Lactobacillus paragrigius* in the preparation of cosmetics, wherein the preservation number of *Lactobacillus paragrigius* is CGMCC No. 36335.

[0024] Preferably, the raw materials for preparing cosmetics include at least one of wheat bran, Pu-erh tea, green tea, black tea, white tea, dark tea, Liubao tea, and black tea.

[0025] The fifth aspect of this invention provides the application of *Lactobacillus paragelius* in inhibiting the proliferation of pathogenic bacteria in vitro, wherein the preservation number of *Lactobacillus paragelius* is CGMCC No. 36335.

[0026] Preferably, the pathogenic bacteria include at least one of Escherichia coli, Staphylococcus aureus, Salmonella, Candida albicans, Pseudomonas aeruginosa, Gardnerella vaginalis, and Atobococcus.

[0027] Preferably, the pathogenic bacteria include Escherichia coli (Escherichia coli). Escherichia coli Staphylococcus aureus ( Staphylococcus aureus ),salmonella( Salmonella enterica Candida albicans ( White albicans ), Pseudomonas aeruginosa ( Pseudomonas aeruginosa Gardnerella vaginalis ( Gardnerella vaginal ) and Atobococcus ( Atopobium minutum At least one of the following.

[0028] According to a specific embodiment of the present invention, *Escherichia coli*, numbered (1) ATCC25922 and CICC10421; *Staphylococcus aureus*, numbered CMCC(B)26001 and CMCC(B)26003, were purchased from the China Medical Bacteriological Preservation and Management Center; *Salmonella* was preferably *Salmonella typhimurium* (…). Salmonella enterica subsp. enterica serovar Typhimurium ), with the code ATCC14028 and Salmonella enteritidis subsp. ( Salmonella enterica subsp. enteric The following bacteria are listed: CVCC3378; Candida albicans is listed as CICC1965 and ATCC10231; Pseudomonas aeruginosa is listed as CICC10419; Gardnerella vaginalis is listed as ATCC14018; and Atobococcus is listed as ATCC33267.

[0029] Existing Lactobacillus paragerens cannot inhibit Candida albicans and / or Atobococcus. Based on this phenomenon, the pathogenic bacteria preferably include Candida albicans and / or Atobococcus.

[0030] The sixth aspect of the present invention provides a heat-inactivated postbiotic, which is prepared from Lactobacillus parageri with accession number CGMCC No. 36335.

[0031] The seventh aspect of the present invention provides a post-lysis biotic, which is prepared from Lactobacillus parageri with accession number CGMCC No. 36335.

[0032] The present invention will be described in detail below through examples. Unless otherwise specified, the reagents and materials used in the following examples are all commercially available products purchased from regular chemical or biological reagent / material suppliers, and all reagents are of analytical grade.

[0033] Reference strains: BNCC367809, *Lactobacillus paragerens*, purchased from Beina Chuanglian Biotechnology Co., Ltd.; BB12, *Bifidobacterium animalis* subsp. *lactamase* (… Bifidobacterium animalum subsp. milk Purchased from Chr. Hansen, Denmark; JCM11657, Lactobacillus gasseri ( Lactobacillus gasseri ZJ316, purchased from the Japan Microbial Culture Collection Center; Lactobacillus plantarum ( Lactiplantibacillus plantarum ), CCTCC No: M208077, purchased from the China Center for Type Culture Collection; LGG, Lactobacillus rhamnosus ( Lactobacillus rhamnosus (ATCC53103), purchased from the American Center for Type Culture Collection.

[0034] Example 1 Method for digesting human colon cancer cells (Caco-2): Cells in logarithmic growth phase with 80% confluence were sterilely pipetted to remove the culture medium. 3 mL of pre-warmed calcium- and magnesium-free PBS was added to cover the cell surface. The cells were incubated for 20 seconds, and the process was repeated once. 0.5 mL of digestive enzyme was added and evenly distributed over the cell layer. The cells were then incubated at 37°C in 5% CO2. Incubate in an incubator until the intercellular spaces significantly increase, then immediately add 1.5 mL of complete culture medium containing serum, gently pipette to obtain a uniform single-cell suspension.

[0035] Digested Caco-2 cells were stored at 10 6 Cells were seeded at a concentration of 10 / mL into six-well plates with coverslips. After 24 h of adherent growth, the cell culture medium containing the antibiotics was removed, and 2 mL of a 10% concentration of antibiotics was added to each well. 8 A CFU / mL CCNH500 bacterial suspension was co-cultured with cells at 37°C and 5 vol% CO2 for 2 h. Unattached strains were washed with PBS buffer, fixed with methanol at room temperature for 20 min, washed with ddH2O, and dried. Gram staining was performed according to the instructions. CCNH500 adhesion was observed under a microscope in 20 randomly selected cells, and the average number of bacteria adhering to each cell (adhesion index) was calculated. A control group (BNCC367809) was also included.

[0036] The adhesion index of CCNH500 was 28.67±2.26 CFU / cell, while the adhesion index of BNCC367809 was only 7.96±1.28 CFU / cell.

[0037] Example 2 Escherichia coli ( Escherichia coli (1) ATCC25922, purchased from the American Center for Type Culture Collection; (2) CICC10421, purchased from the China Industrial Microbial Culture Collection Center. Staphylococcus aureus ( Staphylococcus aureus subsp. golden The items, numbered CMCC(B)26001 and CMCC(B)26003, were purchased from the China Medical Bacteriological Culture Collection Center. Salmonella, (1) Salmonella typhimurium ( Salmonella enterica subsp. enterica serovar Typhimurium ), with the serial number ATCC14028, purchased from the American Center for Type Culture Collection; (2) Salmonella enteritidis subsp. enteritidis ( Salmonella enterica subsp. enteric (with serial number CVCC3378), purchased from the National Veterinary Microbial Culture Collection Center; Candida albicans ( Candida albicans(1) CICC1965, purchased from China Industrial Microbial Culture Collection Center; (2) ATCC10231, purchased from the American Type Culture Collection Center. Pseudomonas aeruginosa ( Pseudomonas aeruginosa (CICC10419), purchased from the China Industrial Microbial Culture Collection Center; Gardnerella vaginalis ( Gardnerella vaginalis ), with the serial number ATCC14018; Atobococcus ( Atopobium minutum (ATCC33267), all purchased from the American Center for Type Culture Collection; Indicator strains of *Escherichia coli*, *Staphylococcus aureus*, *Salmonella*, and *Pseudomonas aeruginosa* were inoculated into LB broth, respectively; *Candida albicans* was inoculated into YPD broth; and *Gardnerella vaginalis* and *Atopobacterium vaginalis* were inoculated into BHI broth mixed with 10% sterile defibrinated sheep blood. The cultures were then incubated overnight in an anaerobic environment at 37°C for activation. After overnight incubation, the indicator bacterial cultures were transferred to their respective fresh culture media and cultured until OD (October Expiratory Scale) was reached. 600 =1 or viable bacteria count 10 8 CFU / mL, diluted to 10 with the appropriate culture medium. 5 CFU / mL was used as the indicator culture. Glycerol tubes of strains CCNH500 and BNCC367809 were inoculated into fresh, sterile MRS liquid medium and incubated overnight at 37°C for 24 h. OD 600 Normalized, the culture medium was inoculated at 2 vol% into fresh MRS liquid medium, and anaerobically cultured at 37°C for 24 h. The supernatant was then centrifuged, sterilized by membrane filtration, and used as the test sample. MRS liquid medium served as a negative control, and ampicillin or kanamycin served as a positive control.

[0038] Reaction system: S1: 100 μL fermentation broth supernatant: 100 μL indicator bacterial solution; S2: 50 μL fermentation broth supernatant: 150 μL indicator bacterial solution; The inhibition rate calculation process is shown below, where A0: OD of negative control sample. 600 Value; A is the OD of the test sample. 600 The values ​​are shown in Table 1.

[0039] Inhibition rate (%) = (A0-A) / A0×100%.

[0040] Table 1

[0041] In Table 1, "-" indicates that no antibacterial activity was detected.

[0042] As can be seen from the results in Table 1, the antibacterial performance of CCNH500 provided by this invention is significantly better than that of BNCC367809.

[0043] Example 3 Acid-producing medium: inulin 20 g / L, peptone 10 g / L, beef meal 10 g / L, yeast powder 5 g / L, magnesium sulfate 0.1 g / L, sodium lactate 1 g / L, ammonium citrate 2 g / L, dipotassium hydrogen phosphate 2 g / L, manganese sulfate 0.05 g / L, Tween 80 1 mL / L.

[0044] Methods for determining lactic acid and acetic acid yields: The yields of lactic acid and acetic acid in the supernatant of the fermentation broth were determined using high-performance liquid chromatography (HPLC). The supernatant was filtered through a 0.22 μm membrane to remove impurities. The chromatographic column was an Aminex HPX-87H (300 mm × 7.8 mm), the mobile phase was 0.005 mol / L H₂SO₄, the temperature was 65℃, the flow rate was 0.6 mL / min, the injection volume was 15 μL, a differential refractive index detector was used, and the analysis time was 30 min.

[0045] Preparation of bacterial culture: 0.2 vol% of the frozen glycerol solution of *Lactobacillus paragelii* was inoculated into fresh MRS liquid medium and incubated statically at 37°C for 24 h in an anaerobic culture station to obtain the seed culture. The seed culture was then transferred to fresh MRS liquid medium at a 2 vol% inoculation rate and incubated anaerobicly at 37°C for 24 h to obtain the bacterial culture.

[0046] The bacterial culture was transferred at 2 vol% to an acid-producing medium and anaerobic incubated for 24 h. The lactic acid production was 9.03 g / L and the acetic acid production was 1.15 g / L. Under this medium, the lactic acid production was higher than that of *Lactobacillus plantarum* CGMCC No. 15013 (lactic acid production 7.6 g / L, acetic acid production 0.57 g / L, described in CN109423467A).

[0047] Example 4 The bacterial culture was centrifuged at 12,000 rpm for 20 min to obtain bacterial sludge. After washing twice with PBS, the PBS was poured off, and a certain amount of sterile water was added to resuspend the culture, which was then concentrated 10 times. The culture was then heat-treated at 100℃ for 30 min and freeze-dried to obtain heat-inactivated biogen. The heat-inactivated biogen was mechanically pulverized using a bead mill and then freeze-dried to obtain lysed biogen.

[0048] Example 5 Hydroxyl radical scavenging rate: The hydroxyl radical scavenging rate of the fermentation broth supernatant was detected using a hydroxyl radical scavenging rate assay kit (Fenton microplate method).

[0049] DPPH free radical scavenging rate: The DPPH free radical scavenging rate of the fermentation broth supernatant was detected using a DPPH free radical scavenging ability test kit (ml092836).

[0050] ABTS + Free radical scavenging rate: bacterial suspension (1×10) 9 0.4 mL of CFU / mL solution was prepared, along with 3.6 mL of ABTS solution (200 mg of 2,2-azino-bis(3-ethyl-benzothiazole-6-sulfonic acid) diammonium salt, 34.4 mg of potassium persulfate, diluted to 50 mL, shaken well, and incubated at room temperature in the dark for 24 h. The solution was then diluted with 95% ethanol to an OD of 0.70 ± 0.02 as the assay solution). The reaction was carried out at room temperature in the dark for 5 min, and the absorption wavelength was detected at 734 nm. The aqueous solution served as a blank control. Glutathione was used as a standard.

[0051] Total reducing power determination: bacterial suspension (1×10⁻⁶) 9 Add 0.5 mL of CFU / mL potassium ferricyanide solution, 0.5 mL of 0.2 mol / L PBS buffer (pH=6), mix well, and react in a 50℃ water bath for 20 min. Then, rapidly cool the mixture in an ice-water bath. Add 0.5 mL of 10% trichloroacetic acid solution, mix well, and transfer to a 5 mL centrifuge tube. Centrifuge at 3000 rpm for 5 min, take 1 mL of the supernatant, add 1 mL of water and 1 mL of 0.1% ferric chloride solution, mix well, and let stand at room temperature for 10 min. Measure the absorbance at 700 nm. The absorbance is directly proportional to the reducing power, so the absorbance represents the total reducing power.

[0052] Additionally, the same method was used to test hydroxyl radicals, DPPH radicals, and ABTS in the heat-inactivated and cleaved biogenic precursors. + Free radical scavenging rate and total reducing power.

[0053] The results are shown in Table 2.

[0054] Free radical scavenging rate (%) = (1 - OD of sample / OD of PBS) × 100%; Table 2

[0055] In the study "A Study on the Antagonistic Effect of Probiotics on Helicobacter pylori in the Feces of Breastfed Newborns", the DPPH free radical scavenging rate of Lactobacillus paragelii XF-35 was 18.57±2.15%, and the ABTS free radical scavenging rate was [missing data]. + The scavenging rate was 67.43 ± 5.60%. This means that the free radical scavenging rate of CCNH500 provided by this invention is high and higher than that of existing Lactobacillus paragelii strains.

[0056] Example 6 Caenorhabditis elegans: purchased from Fujian Shangyuan Biotechnology Co., Ltd.

[0057] Escherichia coli OP50: purchased from Zhili Zhongte (Wuhan) Biotechnology Co., Ltd.

[0058] The bacterial culture obtained after 24 h of CCNH500 culture was centrifuged at 4°C to collect bacterial sludge. The sludge was washed twice with PBS buffer (pH 7.4) and resuspended in M9 buffer to obtain a viable count of 10-1. 8 A bacterial suspension containing CFU / mL was mixed with Escherichia coli OP50 (10⁶ viable bacteria). 8 Mix the CFU / mL bacterial culture at a volume ratio of 1:1, and spread 100 μL of the mixed bacterial culture onto an NCM plate (with 2.5 wt% 5-fluorouracil added). Incubate at 37℃ for 4 h in anaerobically. The blank group is the control group without added probiotic strains. BB12 was selected as the positive control.

[0059] (1) Caenorhabditis elegans in the L4 stage were randomly selected and placed onto NCM plates of each group, 20 nematodes / plate, 3 plates / group, and transferred every 48 h. The experiment ended when all nematodes in all groups died. In addition, the bacterial suspension was replaced with an equal number of viable Escherichia coli OP50, an equal volume of heat-inactivated postbiotics, lysed postbiotics, and BB12 and tested using the same method. The lifespan results of Caenorhabditis elegans in each group are shown in Table 3.

[0060] Table 3

[0061] As shown in Table 3, live CCNH500 bacteria and their postbiotics can significantly prolong the lifespan of nematodes.

[0062] (2) Approximately 1000 L4 stage nematodes were randomly selected into each group. After 3 days, the nematodes were washed 3 times with M9 buffer, ground in liquid nitrogen, centrifuged at 4℃ for 1 min, and the supernatant was collected. The superoxide dismutase (SOD activity) and malondialdehyde (MDA) content were detected by the corresponding kits (Shanghai Enzyme-Link Biotechnology Co., Ltd.). The results are shown in Table 4.

[0063] Table 4

[0064] CCNH500 and its post-biotics can effectively increase the SOD activity of nematodes, reduce the accumulation of MDA in nematodes, and alleviate oxidative damage.

[0065] Example 7 Human skin fibroblasts (HDFs): purchased from Shanghai Yaji Biotechnology Co., Ltd.

[0066] HDFs cells that have reached the logarithmic growth phase were seeded into 6-well cell culture plates and incubated at a constant temperature in a CO2 incubator. The culture medium was then removed, and 2 mL of a 10⁻¹¹ solution was added to each well. 7 Bacterial suspensions and subsequent biotics were prepared using CFU / mL. A buffer solution was used as a blank control, and BB12 as a positive control. The suspensions were irradiated with fluorescent UV lamps for 40 min at an intensity of 0.5 mW / cm². 2 Incubate for 24 h. Fix HDFs cells with formaldehyde-glutaraldehyde solution for 3-5 min, and wash cells twice with PBS. After fixation, stain with X-Gal complex solution. Incubate at 37℃ for 48 h, with each group measured in triplicate. Observe under a bright-field microscope and count the number of photoaged cells (blue cells).

[0067] The number of aged cells in the blank group, CCNH500 bacterial suspension, heat-inactivated postbiotics and lysed postbiotics, and BB12 group were 39.16±2.51, 15.29±1.07, 12.34±0.69, 10.15±0.54, and 17.23±0.94, respectively.

[0068] Example 8 CCNH500 bacterial culture, cultured overnight, was centrifuged, and the bacterial sludge was washed with PBS buffer (pH=7). After resuspending the culture at an equal volume, it was inoculated into black tea infusion (black tea extracted in water at 90℃ for 45 min to obtain fermentation raw material) at a 5 vol% inoculation rate. Fermentation was carried out for 48 h, and the supernatant was collected by centrifugation and sterilized through a 0.22 μm bacterial filter to obtain the cosmetic raw material. The content of antioxidants (tea polyphenols and flavonoids) and free radicals (DPPH free radicals, hydroxyl free radicals, and ABTS) in the fermentation raw material and cosmetic raw material were tested. + The scavenging rate (in %) of free radicals is shown in Table 5.

[0069] The tea polyphenols and flavonoids were determined according to GB / T 31740.2-2015 Tea Products Part 2: Tea Polyphenols and NY / T3903-2021 Determination of Flavonoids from Lycium barbarum. The free radical scavenging rate was determined according to the method in Example 5.

[0070] Table 5

[0071] After fermentation with CCNH500, the content of antioxidant components such as tea polyphenols and flavonoids, as well as the free radical scavenging rate, were all increased. Therefore, this strain can impart higher antioxidant properties to fermentation raw materials.

[0072] The preferred embodiments of the present invention have been described in detail above; however, the present invention is not limited thereto. Within the scope of the inventive concept, various simple modifications can be made to the technical solutions of the present invention, including combinations of various technical features in any other suitable manner. These simple modifications and combinations should also be considered as the content disclosed in the present invention and are all within the protection scope of the present invention.

Claims

1. Lactobacillus paragerens ( Lactobacillus paragasseri Its application in the preparation of formulations for anti-aging, characterized in that, The preservation number of the Lactobacillus paragrigii is CGMCC No. 36335.

2. The application of *Lactobacillus paragelii* in the preparation of antioxidant formulations, characterized in that, The preservation number of the Lactobacillus paragrigii is CGMCC No. 36335.

3. The application of *Lactobacillus paragelii* in in vitro free radical scavenging, characterized in that... The preservation number of the Lactobacillus paragrigii is CGMCC No. 36335.

4. The application according to claim 3, wherein, The free radicals include DPPH free radicals, hydroxyl free radicals, and ABTS. + At least one of the free radicals.

5. The application of *Lactobacillus paragelii* in the preparation of cosmetics, characterized in that... The preservation number of the Lactobacillus paragrigii is CGMCC No. 36335.

6. The application according to claim 5, wherein, The raw materials for preparing cosmetics include at least one of the following: wheat bran, Pu-erh tea, green tea, black tea, white tea, dark tea, Liubao tea, and black tea.

7. The application of *Lactobacillus parageri* in inhibiting pathogenic bacteria, characterized in that, The preservation number of the Lactobacillus paragrigii is CGMCC No. 36335.

8. The application according to claim 7, wherein, The pathogenic bacteria include at least one of Escherichia coli, Staphylococcus aureus, Salmonella, Candida albicans, Pseudomonas aeruginosa, Gardnerella vaginalis, and Atobococcus.

9. A thermally inactivated postbiotic, characterized in that, The heat-inactivated postbiotic was prepared from Lactobacillus parageri as described in claim 1.

10. A post-fracture biotic, characterized in that, The lysed probiotic was prepared from Lactobacillus paragrigii as described in claim 1.

Images